Source comparison
Thymosin Alpha-1 HIV Support Complete Guide 2026: Research Applications Comparison
Adjunct to ART in incomplete immune reconstitution (CD4+ <500 despite viral suppression) 1.6 mg SC twice weekly × 48 weeks Mean CD4+ increase 150–200 cells/μL; enhanced HIV-specific CTL responses Phase III RCT data (n=240+) Primary evidence base. Strongest cli
This comparison does not assign a generated winner or score.
- Adjunct to ART in incomplete immune reconstitution (CD4+ <500 despite viral suppression)
- 1.6 mg SC twice weekly × 48 weeks
- Mean CD4+ increase 150–200 cells/μL; enhanced HIV-specific CTL responses
- Phase III RCT data (n=240+)
- Primary evidence base. Strongest clinical support for this use case
- Treatment-naïve patients initiating ART
- 1.6 mg SC twice weekly × 24 weeks starting with ART initiation
- Reduced inflammatory biomarkers (IL-6, sCD14); no difference in viral suppression rates
- Phase II data (n=120)
- Hypothesis-generating; may address non-AIDS morbidity but requires larger trials
- HIV/HBV or HIV/HCV coinfection
- Improved HBV/HCV-specific T-cell responses; variable effect on viral hepatitis markers
- Small observational studies (n=40–80)
- Mechanistically plausible but insufficient data for clinical recommendation
- Post-ART immune exhaustion (long-term suppressed patients with persistent immune activation)
- 1.6 mg SC twice weekly × 96 weeks
- Reduced immune activation markers; increased naïve T-cell percentages
- Pilot studies (n=30–50)
- Extended duration may be required; cost-benefit unclear
- Monotherapy (without ART)
- Not clinically evaluated
- N/A. No trials conducted
- None
- Thymosin alpha-1 does not suppress HIV replication; always used with ART